Medication info
Lyribea Capsule 75 mg (Pregabalin)

Lyribea Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Brown hard capsule with a white or pale yellow powder inside
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201702210 · Approved 2017.04.28 · Insurance code 694001350

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial-onset seizures)
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dose based on renal function ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children younger than 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial-onset seizures)

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used in adults to relieve peripheral and central neuropathic pain. It also helps as an adjunctive treatment for patients with epilepsy who have partial seizures. Additionally, it is effective in alleviating symptoms associated with fibromyalgia. It is used to alleviate symptoms and improve the quality of life for these three main conditions.

How to take

Adult dose

Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability in the individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dose based on renal function ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children younger than 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; therefore, it is essential to consult a physician immediately if there is any change in mood or behavior during treatment. Patients with hypersensitivity to this medication or those with specific genetic lactose metabolism disorders should not take it. Patients with diabetes should be cautious as weight gain may require adjustment of blood sugar control medications. If swelling occurs around the face or neck while taking this medication, it should be stopped immediately and medical personnel must be informed. Elderly patients may experience dizziness or drowsiness after taking this medication, so extra caution is particularly necessary at the start of treatment due to a possible risk of falls. Temporary blurring of vision or changes in vision may occur; if such symptoms arise, a consultation with a physician is necessary. Discontinuing this medication abruptly may result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so it should be reduced gradually according to a physician's instructions. Patients with a history of substance abuse may be at a higher risk of misuse with this medication and should exercise caution while taking it. Patients with heart or kidney dysfunction should be cautious when taking this medication and may need dose adjustment. Co-administration of this medication with opioid analgesics may increase central nervous system depressant effects, leading to risks such as respiratory distress; caution is advised if taking them together. During early pregnancy, there is a risk of congenital malformations to the fetus; therefore, women who are pregnant or planning to become pregnant should consult with a physician and use effective contraception. Women who are breastfeeding should discuss whether to continue this medication with their physician as it may pass into breast milk and affect the baby. This medication may cause dizziness and drowsiness, so it is advisable to avoid driving or operating hazardous machinery after taking it. Rarely, serious skin reactions may occur; if symptoms such as rash, blisters, or redness appear on the skin, the medication should be discontinued immediately and medical personnel should be informed. In case of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, requiring immediate emergency treatment. This medication should be kept out of reach of children and should not be transferred to other containers for safety.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 200 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • visual changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • respiratory depression
  • major congenital malformations
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • altered sexual sensation
  • restlessness
  • anxiety
  • mood disturbance
  • emotional lability
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • drowsiness
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonic jerks
  • diminished reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • taste loss
  • writing disorders
  • double vision
  • indirect visual loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • eye swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • visual brightness
  • dizziness
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • nasal bleeding
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary dysfunction
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • fatigue
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • seizures
  • shock
  • anaphylaxis-like symptoms
  • skin and mucous membrane syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is important to maintain storage temperatures between 15 and 30 degrees Celsius. Proper storage will help maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

Brown hard capsule with a white or pale yellow powder inside

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.